SEC Form 8-K/A filed by Millendo Therapeutics, Inc. (Amendment)
$MLND
Major Pharmaceuticals
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. ("Tempest"), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (NASDAQ:MLND) ("Millendo"), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. The closing of the merger is anticipated to take place on or around Friday, June 25, 2021. Following the closin
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Tempest Therapeutics, Inc. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today that they have entered into a definitive agreement under which Millendo will merge with Tempest in an all-stock transaction. The combined company will focus on advancing Tempest’s oncology pipeline of small molecule therapeutics that have the potential to address a wide range of tumors. Upon shareholder approval, the combined company is expected to
8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
8-K/A - Millendo Therapeutics, Inc. (0001544227) (Filer)
8-K - Millendo Therapeutics, Inc. (0001544227) (Filer)
3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
SC 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)
SC 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)
SC 13D/A - Millendo Therapeutics, Inc. (0001544227) (Subject)